View Older Stories View More Recent Stories
-
Merck (MRK) in Talks to buy Revolution Medicines (RVMD) - FT
-
Stifel Reiterates Buy Rating on Revolution (RVMD): Will Remain Independent
-
BofA top picks in biotech as sector heading for recovery in 2026
-
After-hours movers: Lockheed Martin, Canadian Solar, Revolution Medicines and more
-
Abbvie: Not In Discussions With Revolution Medicines - Reuters
-
AbbVie in Advanced Talks to Buy Revolution Medicines - WSJ
-
Revolution Medicines (RVMD) halted on circuit breaker following takeover report
-
Oppenheimer on BridgeBio Oncology Therapeutics, In (BBOT): 'We think the lack of idiosyncratic toxicity is particularly notable for BBO-10203'
-
Erasca, Inc (ERAS) Pulls Back from 20+pct Jump, Stifel: 'Today's Strength Driven by Competitor Readthrough'
-
Here's the list of top biotech stocks to own for 2026
-
TD Cowen: 'Revolution (RVMD) Is Our 2026 Best Idea'
-
These stocks are latest additions to Mizuho's Top Picks list
-
Revolution Medicines, Inc. (RVMD) Misses Q3 EPS by 20c
-
RBC Capital Starts Revolution (RVMD) at Outperform
-
Revolution Medicines receives FDA orphan drug status for pancreatic cancer drug
-
Revolution Medicines reports elironrasib data for lung cancer patients
-
Mizuho Starts Revolution (RVMD) at Outperform
-
Revolution (RVMD) PT Raised to $80 at BofA Securities
-
Revolution (RVMD) PT Raised to $76 at Raymond James
-
Stifel Starts Revolution (RVMD) at Buy
-
Raymond James Assumes Revolution (RVMD) at Strong Buy, 'a prime takeout target'
-
Revolution (RVMD) PT Raised to $66 at Needham
-
Truist Securities Starts Revolution (RVMD) at Buy, PT $99
-
Oppenheimer Reiterates Outperform Rating on Revolution (RVMD)
-
Piper Sandler Starts Revolution (RVMD) at Overweight
-
LifeSci Capital Starts Revolution (RVMD) at Outperform
-
Revolution Medicines, Inc. (RVMD) Misses Q2 EPS by 19c
-
Revolution Medicines publishes research on RAS G12D inhibitor in Science
-
Goldman Sachs Starts Revolution (RVMD) at Buy
-
Revolution Medicines partners with Iambic for AI drug discovery
-
H.C. Wainwright Reiterates Buy Rating on Revolution (RVMD)
-
Revolution Medicines (RVMD) and Summit Therapeutics (SMMT) Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors
-
Revolution Medicines (RVMD) Enters Into $2B Flexible Funding Agreement with Royalty Pharma
-
Revolution Medicines (RVMD) Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 Mutations
-
Oppenheimer Reiterates Outperform Rating on Revolution (RVMD)
-
Revolution Medicines (RVMD) Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating Daraxonrasib in Previously Treated Patients with RAS Mutant Non-Small Cell Lung Cancer
-
Revolution (RVMD) PT Lowered to $72 at H.C. Wainwright
-
Revolution Medicines (RVMD) Removed from Raymond James Analyst Current Favorites List
-
Revolution Medicines, Inc. (RVMD) Reports Q1 Loss of $1.13
-
Revolution Medicines (RVMD) Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer
-
Revolution (RVMD) PT Lowered to $64 at Stifel
-
Revolution (RVMD) PT Raised to $73 at H.C. Wainwright
-
Revolution (RVMD) PT Lowered to $59 at Needham
-
Revolution Medicines, Inc. (RVMD) Misses Q4 EPS by 13c
-
2025 Biopharma sector outlook
-
Biotech outlook for 2025: Stifel
-
Biopharma 2025 Preview: 'Piper Sandler Sees Lots of Upside Opportunity'
-
Stifel Highlights Iovanace Biotherapeutics (IOVA) as 'Top Pick' in Biotech's 2025 Outlook Note
-
Revolution (RVMD) PT Lowered to $62 at Needham
-
Revolution Medicines (RVMD) Prices Upsized 14.13M Share Offering at $46/sh
